tirzepatide being discontinued A Major GLP-1 Drug Shortage Is Over. Some Patients Aren't Celebrating FDA confirms tirzepatide shortage is

The main limitation of these studies was the short follow-up time which ranged from a few minutes to 2 weeks in these trials

The compact intercellular tight junctions greatly hinder the transmembrane transport of high-molecular polypeptide drugs

While clinical trials conducted in Croatia in the early 2000s determined BPC 157 to be safe and effective in humans for the treatment of inflammatory bowel disease, there appears to be a lack of trials conducted in the U.S

Discussion An emerging literature indicates that activating central GLP-1Rs is sufficient to reduce cocaine-seeking behavior 8,14,18 , findings that support translational studies focused on re-purposing GLP-1R agonists to treat CUD 5,22